Know Cancer

or
forgot password

Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer


Phase 2
18 Years
N/A
Not Enrolling
Male
Prostate Cancers

Thank you

Trial Information

Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer


Inclusion Criteria:



- Patients must be 18 years of age or older.

- Patients will be scheduled for prostatectomy based on a diagnosis of primary prostate
cancer.

- Ability to lie still for PET scanning

- Patients must be able to provide written informed consent.

Exclusion Criteria:

- Age less than 18

- Inability to lie still for PET scanning

- Cannot provide written informed consent.

- Less than 4 weeks since any prior prostate biopsy (to decrease false positive uptake
from inflammation).

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

We will investigate the ability of anti[18F]FACBC to detect primary prostate carcinoma, and to detect the primary transport mechanism for its uptake

Outcome Time Frame:

At time of scan

Safety Issue:

No

Principal Investigator

David M Schuster, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Emory University

Authority:

United States: Food and Drug Administration

Study ID:

FACBC

NCT ID:

NCT00917865

Start Date:

April 2008

Completion Date:

January 2013

Related Keywords:

  • Prostate Cancers
  • Prostatic Neoplasms

Name

Location
Emory University Hospital Atlanta, Georgia  30322